-$0.17 EPS Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter

Wall Street brokerages predict that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce ($0.17) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.12). Conatus Pharmaceuticals posted earnings per share of ($0.35) during the same quarter last year, which suggests a positive year-over-year growth rate of 51.4%. The company is scheduled to report its next quarterly earnings report on Wednesday, March 21st.

Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Conatus Pharmaceuticals.

CNAT has been the topic of several research analyst reports. Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research report on Thursday, February 8th. They set a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research lowered shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. HC Wainwright reissued a “buy” rating and set a $17.00 target price (down previously from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Finally, S&P Equity Research lifted their target price on shares of Conatus Pharmaceuticals from $5.02 to $5.69 in a research note on Wednesday, January 24th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Conatus Pharmaceuticals currently has an average rating of “Buy” and an average target price of $13.67.

Several large investors have recently modified their holdings of the business. Macquarie Group Ltd. boosted its stake in shares of Conatus Pharmaceuticals by 116.8% during the 4th quarter. Macquarie Group Ltd. now owns 130,300 shares of the biotechnology company’s stock valued at $602,000 after buying an additional 70,200 shares during the period. TIAA CREF Investment Management LLC lifted its stake in shares of Conatus Pharmaceuticals by 28.5% in the 4th quarter. TIAA CREF Investment Management LLC now owns 216,766 shares of the biotechnology company’s stock valued at $1,001,000 after purchasing an additional 48,063 shares during the last quarter. Stone Ridge Asset Management LLC acquired a new stake in shares of Conatus Pharmaceuticals in the 4th quarter valued at $143,000. Geode Capital Management LLC lifted its stake in shares of Conatus Pharmaceuticals by 26.2% in the 4th quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock valued at $1,983,000 after purchasing an additional 89,179 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Conatus Pharmaceuticals by 33.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 141,700 shares of the biotechnology company’s stock valued at $655,000 after purchasing an additional 35,700 shares during the last quarter. 38.77% of the stock is owned by institutional investors.

Conatus Pharmaceuticals (NASDAQ:CNAT) opened at $5.07 on Monday. Conatus Pharmaceuticals has a 52-week low of $3.88 and a 52-week high of $9.40. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69. The firm has a market cap of $154.23, a P/E ratio of -6.26 and a beta of 1.25.

COPYRIGHT VIOLATION WARNING: “-$0.17 EPS Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter” was first reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://weekherald.com/2018/02/15/0-17-eps-expected-for-conatus-pharmaceuticals-inc-cnat-this-quarter.html.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply